Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson's disease.
Motor fluctuations (wearing off) and motor complications (dyskinesia) are common features of the long-term treatment of Parkinson's disease (PD). The basis of both is considered to be a reflection of the progression of neuronal degeneration, coupled with the nature of drug treatment used to control motor symptoms. The concept of continuous dopaminergic stimulation has been used to explain both the onset of wearing off and dyskinesia and their avoidance through pharmacologic manipulation. This review focuses on using with the transdermal dopamine agonist, rotigotine, for continuous dopaminergic drug delivery in the treatment of PD.
Neurodegenerative Diseases Research Group, Institute of Pharmaceutical Sciences, School of Biomedical Sciences, King's College, London, UK. peter.jenner@kcl.ac.uk
Peter
P
Jenner
D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods; D018491:Dopamine Agonists / Q000008:administration & dosage* / Q000097:blood*; D016503:Drug Delivery Systems / Q000706:statistics & numerical data*; D004409:Dyskinesia, Drug-Induced / Q000097:blood* / Q000175:diagnosis; D006801:Humans; D010300:Parkinson Disease / Q000097:blood* / Q000188:drug therapy*; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000097:blood; D013876:Thiophenes / Q000008:administration & dosage / Q000097:blood; D016896:Treatment Outcome
D018491:Dopamine Agonists; D013764:Tetrahydronaphthalenes; D013876:Thiophenes; C047508:rotigotine
Drug delivery; Dyskinesia; Parkinson's disease; Rotigotine; Wearing off